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Legal performance-enhancing substances (PES), such as creatine, are commonly used by
adolescents and young adults. As PES are mostly unregulated by the US Food and Drug
Administration, there has been limited empirical attention devoted to examining their long-
term safety and health outcomes. Preliminary studies have demonstrated associations
between PES use and severe medical events, including hospitalizations and death. PES
could be linked to cardiovascular disease (CVD), the most common cause of mortality in the
US, by altering the myocardium, vasculature, or metabolism. The objective of this study was
to examine prospective associations between the use of legal PES in young adulthood and
CVD risk factors at seven-year follow-up.
Materials and methods
Nationally representative longitudinal cohort data from the National Longitudinal Study of
Adolescent to Adult Health, Waves III (2001–2002) and IV (2008), were analyzed. Regres-
sion models determined the prospective association between the use of legal PES (e.g. cre-
atine monohydrate) and CVD risk factors (e.g. body mass index, diabetes, hypertension,
hyperlipidemia), adjusting for relevant covariates.
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Results
Among the diverse sample of 11,996 male and female participants, no significant differ-
ences by PES use in body mass index, diabetes, hypertension, or hyperlipidemia were
noted at Wave III. In unadjusted comparisons, legal PES users (versus non-users) were
more likely to be White, be male, be college educated, drink alcohol, and engage in weigh-
tlifting, exercise, individual sports, team sports, and other strength training. There were no
significant prospective associations between legal PES use at Wave III and body mass
index, hemoglobin A1c, systolic and diastolic blood pressure, and cholesterol (total, HDL,
LDL, triglycerides) deciles at seven-year follow-up (Wave IV), adjusting for demographics,
health behaviors, and Wave III CVD risk factors. Similarly, there were no significant pro-
spective associations between legal PES use and diabetes, hypertension, or hyperlipidemia
based on objective measures or self-reported medications and diagnoses, adjusting for
demographics, health behaviors, and Wave III CVD risk.
Conclusions
We do not find evidence for a prospective association between legal PES use and CVD risk
factors in young adults over seven years of follow-up, including BMI, diabetes, hypertension,
or hyperlipidemia. It should be noted that legal PES use was operationalized dichotomously
and as one broad category, which did not account for frequency, amount, or duration of use.
Given the lack of regulation and clinical trials data, observational studies can provide much
needed data to inform the safety and long-term health associations of legal PES use and, in
turn, inform clinical guidance and policy.
Introduction
Performance-enhancing substances (PES) are commonly used among adolescents and young
adults and are associated with increased health risks [1, 2]. In the United States (US), PES can
be delineated by legal status, where legal PES include substances such as creatine monohydrate
and amino acids and illegal PES include anabolic-androgenic steroids (AAS) not prescribed
for medical purposes. Research on AAS misuse has documented adverse social, psychological
[3–6], and physiological [7–9] health outcomes, although AAS are less commonly used (3–6%
among boys and men) compared to legal PES [1, 2]. In contrast, between 16–35% of adolescent
and young adult males in the US have used legal PES in the past year [1, 2], with easy accessi-
bility and lack of regulatory oversight of legal PES likely contributing to high use rates. Legal
PES use has also been found to be prospectively associated with AAS misuse [10]. Notably, a
recent study in young people documented that legal PES use, including muscle-enhancing or
energy supplements, was associated with an increased risk of severe medical events (e.g., emer-
gency room visits, disability, or premature death) when compared to vitamin use [11]. Unfor-
tunately, there has been a dearth of research investigating health-related outcomes associated
with legal PES use over the long term [3].
Cardiovascular health outcomes represent an area in particular need of investigation, given
that many cardiovascular disease (CVD) risk factors (e.g., diabetes, hypertension, dyslipide-
mia) commonly develop in young adulthood when legal PES use is prevalent, and CVD
remains the leading cause of death in the US [12, 13]. Legal PES may have effects on the
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cardiovascular system by directly altering the myocardium, vasculature, or metabolism [14].
Furthermore, there is the potential for indirect effects by enabling users to push beyond nor-
mal physiologic limits with potential consequences of exercise-induced arrhythmias [14]. PES
use is associated with eating disorders and muscle dysmorphia [15–17], which have cardiovas-
cular consequences [18, 19]. These potential cardiovascular effects warrant further examina-
tion, especially given mixed findings in various short-term health-related outcomes. For
example, short-term creatine supplementation is generally safe in adults [20], does not appear
to adversely affect blood lipid profiles (e.g., cholesterol, triglycerides) [21], and may even have
favorable glycemic effects (when combined with exercise) for individuals with type-2 diabetes
[22]. However, creatine use also has been linked to weight gain [23], which could represent a
detriment to long-term cardiovascular health, as higher weight and BMI are primary risk fac-
tors for CVD [24]. Additionally, recent reviews have found that stimulants are associated with
significant elevations in systolic and diastolic blood pressure [25, 26]. Caffeine, a stimulant
that can be used for performance enhancement and is commonly included in mixtures of legal
PES, activates the sympathetic nervous system and catecholamines, leading to elevations in
blood pressure [27, 28]. Finally, other legal forms of PES, such as androgen prohormones,
could have particularly deleterious health-related impacts, especially if associated with adverse
cardiovascular effects similar to those resulting from misuse of AAS (which they are designed
to chemically emulate) [20].
Importantly, legal PES are often mislabeled and inaccurate in terms of their contents [11,
29, 30], which may explain serious medical outcomes that can be associated with their use.
Specifically, there are concerns that a significant number of dietary supplementary products
can be adulterated with potent stimulants (e.g., derivatives of methamphetamine) and other
illicit substances (e.g., AAS) [31–34] with serious cardiovascular effects [14]. For instance, 15–
60% of nutritional supplements were found to contain AAS when tested [35, 36]. A recent
review found a link between AAS and CVD risk factors, including hypertension or dyslipide-
mia, in seven of the nine studies reviewed [37], consistent with prior reviews [38–41]. Potential
mechanisms underlying this link include increased systemic inflammation, oxidative stress,
and vascular dysfunction [41]. Consequently, it is plausible that use of a legal PES may pro-
mote CVD risk by virtue of the unlabeled ingredients or contaminants they may contain. Fur-
thermore, amount, frequency, and duration of use are likely to be factors related to adverse
outcomes. For example, high doses and prolonged use of AAS have been found to be associ-
ated with greater degrees of dyslipidemia [41].
In sum, although preliminary research points to a prospective link between legal PES use
and severe medical complications, there is a need to investigate long-term, prospective associa-
tions with specific health outcomes. In the present study, we focus on CVD risk factors–
including diabetes, hypertension, abnormal lipid profiles, and obesity–in young adulthood
given that these outcomes may take many years to fully manifest [38, 42] and evidence suggest-
ing that use of illegal PES (e.g., AAS) is associated with CVD risk factors [37–41]. Additionally,
previous studies have been limited by small and/or highly specific samples (e.g., athletes) or
comparison groups (e.g., vitamin users), warranting further evidence that large sample, popu-
lation-based cohort studies are needed. Thus, the objective of this investigation was to examine
the prospective association between legal PES use in young adulthood and several key CVD
risk factors, using data collected in a nationally representative longitudinal cohort study.
Materials and methods
Study population. This study utilizes data from the National Longitudinal Study of Ado-
lescent to Adult Health (Add Health). Add Health is a nationally representative longitudinal
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cohort study which sampled adolescents throughout the United States and followed them into
adulthood [43]. The baseline sample data was collected from 1994 to 1995 when participants
were 11–18 years old by using systematic sampling methods and implicit stratification so that
the selected high schools (n = 80) and paired middle schools were representative of US schools
with respect to geographical region of the country, size, urbanicity, type (i.e. public, private,
charter), and race/ethnicity. For this specific study, we used the nationally representative,
restricted-use samples from Wave III (18–26 years, 2001–2002) and Wave IV (24–32 years,
2008). At Waves III and IV, data were collected via interview, lasting approximately 90 min-
utes, at the participant’s home or other suitable location. Immediately following the interview,
interviewers took physical measurements and collected biological specimens. The University
of North Carolina Institutional Review Board approved all Add Health study procedures and
written informed consent was obtained. Further details about the study design can be found
elsewhere [43].
Measures. Predictor. The primary predictor variable of this study (asked at Wave III) was
based on the question: “In the past year, have you used a legal performance enhancing sub-
stance for athletes (such as creatine monohydrate or andro)?” Response choices included “yes”
or “no.”
Outcomes. The primary outcome measures of this study are listed below and included mea-
surements of several CVD risk factors, such as body mass index (BMI), hemoglobin A1c,
blood pressure, and cholesterol at Wave IV.
Body mass index (BMI). was calculated using the standard formula weight (kilograms)
divided by height (meters) squared (BMI = weight/height2). Weight (Health-o-meter 844KL
High Capacity Digital Bathroom Scale; Jarden Corporation; Rye, NY) and height (Carpenter’s
square, steel tape measure) were measured by the interviewer. Change in BMI was calculated
as Wave IV BMI minus Wave III BMI (e.g., positive values indicate BMI gain).
Hemoglobin A1c. We examined hemoglobin A1c in Wave IV as a continuous outcome.
Respondents in the study were also classified as having diabetes in Wave IV if they had levels
of fasting glucose� 126 mg/dl, non-fasting glucose� 200 mg/dl, and hemoglobin A1c� 6.5%
[44], had a self-reported history of diabetes (except during pregnancy), or if they used anti-dia-
betic medication in the four weeks preceding the Wave IV assessment. We included self-
reported diagnosis of diabetes at Wave III as a covariate.
Blood pressure. We examined systolic and diastolic blood pressure as continuous outcomes,
using the mean of two measurements separated by a 30 second interval from a factory-cali-
brated, Microlife BP3MC1-PC-IB oscillometric blood pressure monitor (MicroLife USA, Inc.;
Dunedin, FL). Hypertension was defined as a measured systolic blood pressure�130 mmHg
or a measured diastolic blood pressure�80 mmHg [45], the use of anti-hypertensive medica-
tion in the four weeks preceding the Wave IV assessment, or an affirmative response to the
query: “Have you ever been diagnosed with high blood pressure or hypertension?” In 2017, the
American College of Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines lowered the threshold for systolic and diastolic blood pressure to define hyperten-
sion (130/80 from 140/90), expanding the number of young adults with hypertension [45].
This choice was based on meta-analyses of observational studies that demonstrated that ele-
vated blood pressure and hypertension are associated with increased risk of CVD, end stage
renal disease, subclinical atherosclerosis, and all-cause death [45]. We included self-reported
diagnosis of high blood pressure or hypertension at Wave III as a covariate.
Cholesterol. Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipo-
protein (LDL) cholesterol, and triglyceride deciles were defined as continuous outcomes for
this study. Hyperlipidemia was defined as the total cholesterol decile corresponding to the pro-
portion of young adults with a total cholesterol�240 mg/dL in the nationally representative
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National Health and Nutrition Examination Surveys [12, 46], the use of antihyperlipidemic
medication in the four weeks preceding the Wave IV assessment, or an affirmative response to
the question: “Have you ever been diagnosed with high cholesterol, triglycerides, or lipids?”
We included self-reported diagnosis of high cholesterol, triglycerides, or lipids at Wave III as a
covariate.
Additional covariates. Included self-reported demographics such as age, sex, race/ethnicity,
highest education (high school or less versus college or more), and household income, as these
have been shown to be associated with both legal PES use [47] and CVD risk [48]. We evalu-
ated household income as a covariate with data from parents’ self-report of household income
in the last calendar year. Gaussian normal regression imputation models were used to impute
the income for the 1,638 parents who did not respond, were uncomfortable answering the
income question, or stated that they did not know, similar to the method used in previous
studies [2]. Behavioral covariates that are associated with legal PES use and CVD risk [12, 47,
49] were assessed at Wave III, including self-reported alcohol use (�2 days in the past month,
yes/no), smoking (past 30 days, yes/no), AAS use (between Wave I and III, yes/no), and physi-
cal activity and sports context, including weight lifting to bulk up in the past 7 days (yes/no),
exercising to bulk up in the past 7 days (yes/no), the number of times participating in individ-
ual sports (running, wrestling, swimming, cross-country skiing, cycle racing, or martial arts)
in the past 7 days (0–7), the number of times participating in strenuous team sports (football,
soccer, basketball, lacrosse, rugby, field hockey, ice hockey) in the past 7 days (0–7), and the
number of times participating in gymnastics, weight lifting, or strength training in the past 7
days (0–7).
Statistical analysis
Data analysis was performed using Add Health’s pre-constructed sample weights to provide a
sample that was nationally representative [50]. Comparisons of descriptive characteristics
between legal PES users versus non-users of legal PES were calculated using Pearson’s Chi-
square tests for categorical variables and independent sample t-tests for continuous variables.
Multiple linear regression models were used to evaluate the association between legal PES use
(Wave III) and continuous CVD risk factors, including BMI, BMI change, hemoglobin A1c,
systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, and
triglyceride deciles (Wave IV). Multiple logistic regressions were used to evaluate the associa-
tion between legal PES use (Wave III) and subsequent dichotomous clinical CVD risk factors,
including diabetes, hypertension, hyperlipidemia, and obesity (Wave IV). For each outcome,
we present three regression models: 1) unadjusted, 2) adjusted for demographics and baseline
CVD risk (adjusted for age, sex, race/ethnicity, BMI, and self-reported hypertension, hyperlip-
idemia, or diabetes at Wave III), and 3) fully adjusted (adjusted for age, sex, race/ethnicity,
household income, highest education, smoking, alcohol, AAS, weightlifting, exercise, strength
training, individual sports, team sports, BMI, and self-reported hypertension, hyperlipidemia,
or diabetes at Wave III). Wave III and Wave IV measures of smoking, alcohol, strength train-
ing, individual sports, and team sports were included in the fully adjusted model. Analyses
were conducted using Stata 15.1 (StataCorp, College Station, TX).
Power calculations. Given a sample size of legal PES users (n = 963) and non-users
(n = 11,033), and using an estimated mean for i) BMI change (Wave III to IV): 2.5±4.3 kg/m2,
and ii) BMI (Wave IV): 29.0±7.5 kg/m2, our study had statistical power (alpha = .05, two-
sided) of>80% to detect a i) 0.4 kg/m2 group difference in BMI change and ii) 0.7 kg/m2
group difference in BMI at Wave IV. Using an estimated mean for i) hemoglobin A1c 5.59
±0.80%, ii) systolic blood pressure of 125.02±13.69 mmHg, iii) diastolic blood pressure of
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79.37±10.21 mmHg, and iv) cholesterol deciles of 5.44±2.88, our study had statistical power
(alpha = .05, two-sided) of>80% to detect a i) 0.08% group difference in hemoglobin A1c, ii)
1.28 mmHg group difference in systolic blood pressure, iii) 0.96 mmHg group difference in
diastolic blood pressure, and iv) 0.27 group difference in cholesterol deciles. Given a sample
size of legal PES users (n = 963) and non-users (n = 11,033), and using an estimated i) 6.5%
with diabetes, ii) 51.9% with hypertension, and iii) 16.6% with hyperlipidemia, our study had
statistical power (alpha = .05, two-sided) of>80% to detect odds ratios of i) 1.21 for hyperten-
sion, ii) 1.28 for hyperlipidemia, and iii) 1.41 for diabetes, respectively.
Results
Overall, the 11,996 participants included in the analysis were on average 22 years of age at
Wave III and were racially and ethnically diverse. Comparisons of descriptive and health char-
acteristics of the sample are presented in Table 1, organized by legal PES use versus no use. In
unadjusted comparisons, legal PES users were more likely to be White, male, college-educated,
drink alcohol, and engage in weightlifting, exercise, individual sports, team sports, and other
strength training than non-users. Legal PES users had higher parental household income than
non-users. Frequency of health behaviors such as alcohol, smoking, and physical activity
remained relatively stable over seven-year follow-up, except for the number of times partici-
pating in team sports, which decreased over follow-up. There were no significant differences
in BMI or self-reported diabetes, hypertension, or hyperlipidemia diagnoses between PES
users and non-users at Wave III. During the seven-year follow-up period, prevalence of diabe-
tes, hypertension, and hyperlipidemia increased.
Table 2 presents linear regression models with legal PES use as the independent variable
and continuous CVD risk factors at seven-year follow-up as the dependent variable. In unad-
justed linear regression models, legal PES use was associated with higher systolic blood pres-
sure, a lower HDL cholesterol decile, and a higher triglyceride decile. In models adjusting for
demographics, health behaviors, and Wave III CVD risk, there were no significant prospective
associations between legal PES use and BMI, hemoglobin A1c, systolic blood pressure, and
cholesterol (total, HDL, LDL, triglycerides) deciles at seven-year follow-up except for diastolic
blood pressure. Legal PES use was associated with lower diastolic blood pressure in partially
adjusted models, but the association was attenuated and was no longer statistically significant
after adjusting for behavioral covariates. Table 3 presents logistic regression models with legal
PES use as the independent variable and dichotomous CVD risk factors at seven-year follow
up as the dependent variable. There were no significant prospective associations between legal
PES use and diabetes, hyperlipidemia, or obesity based on objective measures or self-reported
medications and diagnoses, adjusting for demographics, health behaviors, and Wave III CVD
risk at seven-year follow-up. Legal PES use was associated with lower odds of hypertension in
partially adjusted models, but the association was attenuated and was no longer statistically sig-
nificant after adjusting for behavioral covariates.
Discussion
In this nationally representative cohort study of nearly 12,000 young adults in the US, we did
not find significant prospective associations between legal PES use and CVD risk factors,
including blood pressure, diabetes, lipids, and BMI, when adjusting for theoretically relevant
covariates. Legal PES use was more common among males and participants with White race,
higher education, higher income, alcohol use, and engagement in weightlifting, exercise, indi-
vidual sports, team sports, and other strength training. Given the pervasive use of legal PES
and current proposed legislation regarding the sale of legal PES to minors, research on long-
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Table 1. Descriptive and health characteristics of 11,996 young adult participants in the National Longitudinal Study of adolescent health.
Legal PES Use No legal PES
Use
N 963 11,033
Demographic characteristics (Wave III, 18–26 years) Mean ± SE /
%a
Mean ± SE / %a p





White (non-Hispanic) 77.0% 67.6%
Black/African American (non-Hispanic) 9.1% 16.0%
Hispanic/Latino 9.9% 12.0%
Asian/Pacific Islander (non-Hispanic) 2.5% 3.1%
American Indian/Native American 0.6% 3.2%
Other 0.9% 0.8%
Household income, US dollars (Wave I, 11–18 years old) 52.7 ± 2.1 45.4 ± 1.4 <0.001
College education or more (Wave IV, 24–32 years old) 82.8% 73.6% <0.001
Health behaviors (Wave III, 18–26 years old)
Alcohol use,�2 days in the past month 69.2% 43.9% <0.001
Smoking, past 30 days 38.7% 35.5% 0.181
Weight lifting to bulk up, past 7 days 33.6% 6.0% <0.001
Exercise to bulk up, past 7 days 29.3% 6.4% <0.001
Number of times participated in individual sports (running, wrestling, swimming, cross-country skiing, cycle racing, or
martial arts), past 7 days
1.2 ± 0.1 0.6 ± 0.0 <0.001
Number of times participated in strenuous team sports (football, soccer, basketball, lacrosse, rugby, field hockey, ice
hockey), past 7 days
0.9 ± 0.1 0.4 ± 0.0 <0.001
Number of times participated in gymnastics, weight lifting, or strength training, past 7 days 2.6 ± 0.1 0.8 ± 0.0 <0.001
Anabolic androgenic steroid use, between Wave I and III 13.7% 0.80% <0.001
Health behaviors (Wave IV, 24–32 years old)
Alcohol use,�2 days in the past month 68.8% 46.1% <0.001
Smoking, past 30 days 38.3% 37.6% 0.789
Number of times participated in individual sports (running, wrestling, swimming, cross-country skiing, cycle racing, or
martial arts), past 7 days
1.2 ± 0.1 0.7 ± 0.0 <0.001
Number of times participated in strenuous team sports (football, soccer, basketball, lacrosse, rugby, field hockey, ice
hockey), past 7 days
0.5 ± 0.0 0.3 ± 0.0 <0.001
Number of times participated in gymnastics, weight lifting, or strength training, past 7 days 2.0 ± 0.1 0.8 ± 0.0 <0.001
Physical health factors (Wave III, 18–26 years)
Body mass index 26.2 ± 0.2 26.5 ± 0.1 0.176
Diabetes, self-report 1.1% 0.9% 0.774
Hypertension, self-report 6.1% 5.5% 0.626
Hyperlipidemia, self-report 4.0% 4.3% 0.746
Physical health factors (Wave IV, 24–32 years old)
Body mass index 28.7 ± 0.2 29.1 ± 0.2 0.230
Diabetes, self-report 2.1% 2.7% 0.323
Diabetes, self-report, hemoglobin A1c, medications 5.9% 6.6% 0.474
Hemoglobin A1c 5.6 ± 0.0 5.6 ± 0.0 0.802
Hypertension, self-report 14.9% 10.5% 0.007
Hypertension, self-report, blood pressure, medications 58.0% 51.3% 0.012
Systolic blood pressure 128.8 ± 0.6 124.7 ± 0.2 <0.001
(Continued)
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term health effects of legal PES are warranted, especially given the paucity of studies and the
lack of regulation by the Food and Drug Administration.
Our findings are consistent with earlier empirical research suggesting that legal PES use has
few harmful effects on key risk factors for CVD. Previous research indicates that short- and
long-term engagement of common PES, such as creatine and pre-workout supplements, do
not pose a risk with respect to blood lipid profiles or hemodynamic properties [21, 51]. Our
study extended these prior results, which were limited to a small sample of athletes, to investi-
gate health outcomes of legal PES users over a longer time period in a much larger, general
population sample without medical oversight. Additionally, although previous research has
found an association between creatine use and weight gain [23], we did not find such a link,
even in unadjusted analyses. This lack of association may provide a primary explanation for
why we did not find an association between legal PES use and CVD risk, as weight and BMI
are primary risk factors for CVD [24]. This may be in part due to our longer seven-year fol-
low-up period, as well as the dichotomous operationalization of legal PES use and the overall
broader conceptualization of legal PES that was not restricted to creatine only.
Table 1. (Continued)
Legal PES Use No legal PES
Use
Diastolic blood pressure 80.2 ± 0.5 79.3 ± 0.2 0.058
Hyperlipidemia, self-report 8.6% 8.2% 0.778
Hyperlipidemia, self-report, labs, medications 14.8% 16.7% 0.256
Total cholesterol decile 5.5 ± 0.1 5.6 ± 0.1 0.836
LDL cholesterol decile 5.6 ± 0.2 5.6 ± 0.1 0.986
HDL cholesterol decile 4.9 ± 0.1 5.5 ± 0.1 <0.001
Triglyceride decile 5.9 ± 0.1 5.6 ± 0.1 0.015
PES = performance-enhancing substance (such as creatine monohydrate or andro)
aAll means and percentages are calculated with weighted data to reflect the representative proportion in the target US population.
https://doi.org/10.1371/journal.pone.0244018.t001
Table 2. Associations between legal performance-enhancing substance use and continuous cardiovascular disease risk factors among young adults at seven-year fol-
low-up.
Seven-year follow-up outcomes (ages 24–32 years) Unadjusted Adjusted, demographicsa Fully adjustedb
Cardiovascular disease risk factors B (95% CI) p B (95% CI)a p B (95% CI)b p
Hemoglobin A1c -0.01 (-0.08–0.06) 0.802 -0.04 (-0.11–0.02) 0.194 0.02 (-0.07–0.10) 0.669
Systolic blood pressure 4.15 (2.96–5.34) <0.001 -0.49 (-1.69–0.72) 0.427 0.13 (-1.15–1.41) 0.838
Diastolic blood pressure 0.90 (-0.03–1.84) 0.058 -1.38 (-2.36 - -0.41) 0.006 -0.69 (-1.73–0.36) 0.197
Total cholesterol decile 0.03 (-0.32–0.26) 0.836 -0.15 (-0.45–0.14) 0.306 -0.15 (-0.46–0.17) 0.358
LDL cholesterol decile 0.00 (-0.32–0.32) 0.986 -0.11 (-0.43–0.21) 0.503 -0.14 (-0.49–0.21) 0.424
HDL cholesterol decile -0.54 (-0.81 - -0.28) <0.001 -0.02 (-0.29–0.25) 0.885 -0.15 (-0.43–0.14) 0.312
Triglyceride decile 0.32 (0.06–0.58) 0.015 -0.26 (-0.53–0.01) 0.059 -0.07 (-0.37–0.24) 0.665
Body mass index -0.33 (-0.88–0.21) 0.230 -0.01 (-0.36–0.34) 0.958 0.18 (-0.19–0.55) 0.329
Body mass index change 0.00 (-0.36–0.35) 0.990 0.01 (-0.37–0.38) 0.971 0.15 (-0.26–0.56) 0.468
aAdjusted for age, sex, race/ethnicity, and BMI, hypertension, hyperlipidemia, or diabetes at Wave III.
bAdjusted for age, sex, race/ethnicity, household income, highest education, smoking,� alcohol,� anabolic-androgenic steroid use, weightlifting, exercise, strength
training,� individual sports�, team sports�, BMI, and hypertension, hyperlipidemia, or diabetes at Wave III. � indicates adjusted for measures at both Wave III and Wave
IV.
https://doi.org/10.1371/journal.pone.0244018.t002
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Additionally, our study adjusted for a large number of theoretically salient sociodemo-
graphic, behavioral, and health-related covariates, which were not accounted for in previous
research. For example, Or and colleagues only controlled for age and gender [11], whereas in
our study, the significant prospective associations between legal PES use and CVD risk that
were found in unadjusted models were no longer significant when adjusting for Wave III
CVD risk, broader sociodemographics, and other relevant behavioral variables. Thus, the asso-
ciation between legal PES and medical outcomes may be an indirect one, accounted for by the
propensity of legal PES users to engage in other risky behaviors and to develop substance use
and mental disorders. Further, Or and colleagues’ comparison group was composed of vitamin
users, a subset of the population that have been shown to exhibit better health outcomes com-
pared to the general population [52, 53]. Thus, the pro-health behaviors in that population
may have contributed to the significant differences detected in that study moreso than the del-
eterious effects of PES. Finally, it is possible that the association between PES use and severe
medical events may not be specifically related to CVD risk factors and may instead be the
result of deleterious impacts on other organ systems (e.g., renal dysfunction [23]).
Strengths and limitations
There are several limitations regarding the assessment of legal PES use. First, legal PES use was
assessed as one broad category. While some examples were provided (such as creatine or
andro), the Add Health survey did not list all examples of legal PES, which could also include
β-alanine, L-carnitine, energy drinks, or others. Specific types of legal PES, such as those con-
taining surreptitious AAS, selective androgen receptor modulators (SARMs), or other anabolic
substances that are technically legal but sold primarily over the internet, could have associa-
tions with CVD risk; however, we were unable to separately analyze distinct types of legal PES.
Second, the legal PES measure (yes/no) did not assess frequency, amount, or duration of use.
It is possible that detecting significant associations with the health-related outcomes assessed
here would require more precise dose- and duration-specific data. This is consistent with the
notion that lasting physiological effects of substance use, including AAS [42], are exacerbated
with longer duration and higher amounts of use. Third, the Add Health survey did not collect
legal PES data at Wave IV so information on the rate maintaining legal PES use over a seven-
year period is not available. Further, the concurrent use of multiple PES (e.g., creatine, pre-
workout, prohormones as part of a PES regimen) could also be more likely to be significantly
associated with greater CVD risk. In the current study, short-term, infrequent, and/or minimal
use was indistinguishable from long-term, frequent, and high levels of use, and this
Table 3. Associations between legal performance-enhancing substance use and binary clinical cardiovascular disease risk factor outcomes among young adults at
seven-year follow-up.
Seven-year follow-up outcomes (ages 24–32 years) Unadjusted Adjusted, demographicsa Fully adjustedb
Cardiovascular disease risk factors Odds ratio (95% CI) p Odds ratio (95% CI)a p Odds ratio (95% CI)b p
Diabetes 0.88 (0.62–1.26) 0.496 0.94 (0.66–1.34) 0.713 1.37 (0.93–2.02) 0.107
Hypertension 1.31 (1.06–1.62) 0.012 0.78 (0.62–0.97) 0.027 0.86 (0.68–1.10) 0.232
Hyperlipidemia 0.86 (0.67–1.12) 0.276 0.83 (0.62–1.10) 0.198 0.94 (0.70–1.26) 0.676
Obesity 0.93 (0.78–1.11) 0.414 1.08 (0.87–1.34) 0.505 1.25 (0.98–1.59) 0.069
aAdjusted for age, sex, race/ethnicity, and BMI, hypertension, hyperlipidemia, or diabetes at Wave III.
bAdjusted for age, sex, race/ethnicity, household income, highest education, smoking,� alcohol,� anabolic-androgenic steroid use, weightlifting, exercise, strength
training,� individual sports�, team sports�, BMI, and hypertension, hyperlipidemia, or diabetes at Wave III. � indicates adjusted for measures at both Wave III and Wave
IV.
https://doi.org/10.1371/journal.pone.0244018.t003
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heterogentity likely limited our ability to detect significant effects. Future research should
assess the type, dose, and frequency of legal PES use in relation to future CVD risk.
In addition to the limitations regarding the assessment of PES use described above, another
potential limitation of the study includes the use of self-reported measures, which could lead
to reporting bias. We attempted to mitigate this by incorporating self-report of a physician
diagnosis and objective measures into the Wave IV outcomes (the objective measures were not
recorded at Wave III). Further, although the follow-up period in this study was seven years, it
is possible that the medical and physiological effects of PES use, particularly if prolonged,
emerge after a longer period of time or in age groups older than the young adult range
reflected in the current sample. Although we adjusted for a large number of potential con-
founders, it is possible there were unmeasured confounders we were not able to adjust for. For
instance, while we adjusted for frequency of sports participation, Add Health did not collect
data on physical activity intensity or duration. Despite these limitations, however, there were
numerous strengths to this study. First, we investigated a large, nationally representative sam-
ple and addressed an under-researched topic with important policy implications. Additionally,
we extended the existing literature in this area by accounting for numerous theoretically-
important covariates related to CVD risk which have not typically been included in previous
studies on this topic. Further, the long-term, prospective nature of the study design contributes
to the literature that has often focused on only short-term or immediate effects.
Conclusions
While our study found no significant prospective associations between legal PES use and CVD
risk factors, there remains a need for ongoing research into the long-term health outcomes of
legal PES use. As noted by Pope et al. (2014), it is unlikely that randomized controlled trials
will be conducted to test the outcomes of these substances [38]. This is in part due to the lack
of funding, the unregulated nature of PES, and the potential risks associated with administer-
ing supraphysiologic doses of PES in clinical trials. Therefore, despite certain limitations inher-
ent to their design, longitudinal cohort studies will represent invaluable sources of future data
on the outcomes associated with legal PES use. Further, it will be important to account for the
many confounding factors that may either exacerbate or protect against any potential adverse
health outcomes. This may include exercise duration and intensity, dietary intake and eating
patterns, health care utilization, income, stress, medical and mental health history, other sub-
stance use or misuse, and family medical and mental health history. Future research should
investigate both the benefits and risks associated with legal PES use across age groups, as well
as explore outcomes relevant to other organ systems of the body, such as the renal and liver
systems.
In sum, there is growing evidence that legal PES use is common among adolescents and
young adults, particularly among boys and men [1, 2], and these substances are unregulated
and easily accessible in the US [3]. Despite the null findings in this study, prior research indi-
cated that adverse health [11] and social [10, 47] outcomes are associated with legal PES use
and our unadjusted models indicated that legal PES use was associated with certain CVD risk
factors after seven years; however, it was apparent that other sociodemographic and behavioral
variables better explained this association, as the associations were no longer significant in the
fully adjusted models. Amid the lack of federal policy and oversight in the US, state policies
have been introduced that aim to regulate the sale of these substances to minors, as well as pro-
vide detailed labeling that outlines the lack of oversight and research on outcomes associated
with their use [54, 55]. Given these policies, it is imperative that research be funded and con-
ducted to provide data on the safety and health effects, both risks and benefits, of legal PES use
PLOS ONE Performance-enhancing substances and cardiovascular disease risk
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in order to inform public policy. Lastly, implementation and evaluation science will be needed
to assess the effectiveness of any policies passed into law.
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